NeuroBo Pharmaceuticals Inc. filings, under the MetaVia Inc. registrant name after its name change, document a clinical-stage biotechnology issuer centered on cardiometabolic drug development. Recent Form 8-K disclosures include quarterly results and corporate updates, Regulation FD materials, corporate presentations, and press releases related to DA-1726 for obesity and DA-1241 for MASH.
The filing record also covers stockholder-meeting matters, including director elections, auditor ratification, executive-compensation advisory votes, reverse stock-split authorization proposals, Nasdaq share-issuance proposals, and common stock voting mechanics. These disclosures frame the company's governance, capital structure, clinical-development communications, and Exchange Act reporting obligations.
MetaVia Inc. Reporting persons Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 1,270,887 shares of MetaVia common stock, representing 4.99% of the class. Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares reported. Mr. Boyd, as managing member of Armistice Capital, is also reported as having shared voting and dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Woodworth Marshall H, listed as Chief Financial Officer, reported a Form 4 for MetaVia Inc. (MTVA) showing a transaction dated 08/12/2025. The filing records a transaction code G and shows acquisition of 14,200 shares at a price of $0, bringing his beneficial ownership to 30,079 shares. The Form 4 was executed by a power of attorney on 08/13/2025 and includes Exhibit 24 (Power of Attorney).
MetaVia Inc. Form 8-K — Regulation FD disclosure (Aug 6, 2025)
MetaVia furnished a press release announcing an extension of the 48 mg multiple ascending dose (MAD) cohort in the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks and reporting that a fifth weekly dose was administered to the first patient. DA-1726 is described as a novel dual oxyntomodulin (OXM) analog agonist acting at GLP1R and GCGR for obesity treatment.
- Date: August 6, 2025
- Action: Cohort duration extended to 8 weeks (from 4 weeks)
- Dosing update: Fifth weekly dose given to first patient
- Exhibit: Press release furnished as Exhibit 99.1 (information furnished, not filed)